# A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

> **NCT01000740** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **GENETIC:** EGFR Mutation Test
- **GENETIC:** Ki-67 protein expression

## Key facts

- **NCT ID:** NCT01000740
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2010-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000740, "A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01000740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*